CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

CRISPR Therapeutics trades at a significant discount despite Wall Street analysts rating 58% as buy with 437% upside potential. The company's first commercialized product, Casgevy, treats sickle cell disease and beta thalassemia. With only 64 patients treated in 2025 and $4.1M in sales, analysts project revenue growth to $43.9M in 2026 and $151.6M in 2027. A strong pipeline of five additional therapies in clinical trials and a large addressable market of 60,000 eligible patients position CRISPR as a potential long-term growth opportunity, though highly speculative.